Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on IO Biotech — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plans Book a 15-min walkthrough

▶

Watch the 2-minute tour · with sound

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Dec 20, 2024•over 1 year ago

Contract Type

agreement

Copenhagen

Description

IO Biotech, a clinical-stage biopharmaceutical company, has secured a loan facility of up to €57.5 million from the European Investment Bank (EIB) to fund the continued development and pre-commercialization of IO102-IO103 and other therapeutic cancer vaccine candidates.

Company Information

Company

IO Biotech

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

Predictive Intelligence

Strategic

ML-powered predictions for IO Biotech's next move

Learn about Strategic plan

Related People

Suggested for you

Agreement Insights

Based on industry data

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months